NEXUS Nanodomain Engineering using a X-omics blueprint of the NK cell Surface
- Coordinator
- Stichting Radboud Universitair Medisch Centrum, Netherlands
- Runs
- 1 January 2027 to 31 December 2031
- Status
- Running
- EU funding
- €1.5m
- Total cost
- €1.5m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101300437
What the project is doing
In the project's own words, from its summary on CORDIS.
Natural killer (NK) cells hold enormous promise for cancer therapy, which is explored in nearly 400 clinical trials. Yet, on average only about 40% of patients respond to treatment and it remains difficult to predict why. This challenge stems from a fundamental unknown: how do NK cells decide whether to kill a tumor cell? Traditional models assume this decision is governed by a simple balance of activating and inhibitory receptors, but mounting evidence suggests a more intricate mechanism: the nanoscale spatial organization of these receptors appears to encode specific instructions that determine NK cell behavior.
I project that a proximity labeling platform I recently developed represents a key foundation to decipher this code. In my ERC project called NEXUS I will:1) Apply a new cutting-edge nanoscale proteomics approach to systematically chart the nanoscale distribution of key NK receptors and their coregulators on the membrane of cultured and primary human NK cells across various activating and repressive conditions. 2) Develop a new spatial interaction proteomics approach to define which receptor-ligand interactions guide NK recognition of tumor targets.3) Engineer NK cells with optogenetically tunable receptor clustering to causally test how specific receptor organizations govern NK cell activation, immune synapse formation, and target killing.
Together, NEXUS will redefine our understanding of NK cell biology and establish a generalizable framework for how immune cells interpret complex signals through spatial organization. This could open an entirely new dimension of immune regulation and reshape the way we think about immune decision-making, and move immunotherapy design beyond trial-and-error towards new rational, spatially informed NK-cell therapies with transformative potential for cancer treatment.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI